Venous thromboembolism (VTE)
Blood clots in the leg veins or lungs. Cancer makes blood clot more easily and some treatments (IMiDs, anti-VEGF drugs, hormone therapy, central lines, surgery) add risk; clots are the second commonest cause of death in cancer patients after the cancer itself.
Cancer-associated thrombosis affects 5-20% of patients, highest in pancreatic, gastric, brain and lung cancer and myeloma; the Khorana score identifies outpatients who benefit from prophylactic apixaban or rivaroxaban (AVERT, CASSINI). Treatment is a DOAC or low-molecular-weight heparin for at least 6 months, balancing bleeding risk in gastrointestinal and urothelial tumours. Lenalidomide and thalidomide mandate aspirin or anticoagulant prophylaxis; bevacizumab and other VEGF inhibitors raise arterial events; tamoxifen and erythropoiesis-stimulating agents raise venous ones. Incidental pulmonary emboli on staging CTs are common and are treated as symptomatic ones.
Pages like this
not linked directly; found by shared links- TermVRd and Dara-VRd (myeloma induction regimens)
Shares Immunomodulatory drugs (IMiDs) and CELMoDs, Lenalidomide.
- TechnologyAnti-angiogenic therapy
Shares Thalidomide, Cancer-associated thrombosis prevention and treatment, Anti-VEGF class toxicities (hypertension, proteinuria, bleeding, perforation), Bevacizumab.
- PathwayIntravasation & circulating tumour cells
Shares Cancer-associated thrombosis prevention and treatment, Bevacizumab.
- TechnologyPROTACs & molecular glues (targeted protein degradation)
Shares Thalidomide, Immunomodulatory drugs (IMiDs) and CELMoDs, Lenalidomide.